Mingye Zhao

机构：China Pharmaceutical University · ORCID：0000-0002-7709-9374

发表论文 46 篇 · 总被引 489 次 · h-index 14

代表论文

• Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis (2024 · BMC Cancer · 被引 21)
• A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer (2024 · BMC Medicine · 被引 18)
• Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis (2024 · BMC Cancer · 被引 15)
• Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs (2025 · JAMA Network Open · 被引 10)
• Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective (2024 · Cost Effectiveness and Resource Allocation · 被引 10)
• Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China (2023 · BMC Public Health · 被引 6)